Searchable abstracts of presentations at key conferences in endocrinology

ea0035p898 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Recurrence of hyperprolactinemia after withdrawal of cabergoline in prolactinomas

Sala Elisa , Bellaviti Paola , Ferrante Emanuele , Malchiodi Elena , Verrua Elisa , Giavoli Claudia , Profka Eriselda , Beck-Peccoz Paolo , Spada Anna , Mantovani Giovanna

Introduction: The optimal treatment duration for prolactinomas to minimize reccurences is not clear. 2011 Endocrine Society Guidelines suggested that cabergoline withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor volume reduction.Materials and methods: We analyzed 74 patients (mean age=46.9±14.4, M/F=19/56, macro/micro=18/56) bearing a prolactinoma. Patients were divided in 3 groups: Group A (23) tre...